Antiviral drug allergy.
Identifieur interne : 003575 ( PubMed/Corpus ); précédent : 003574; suivant : 003576Antiviral drug allergy.
Auteurs : Brigitte Milpied-Homsi ; Ellen M. Moran ; Elizabeth J. PhillipsSource :
- Immunology and allergy clinics of North America [ 1557-8607 ] ; 2014.
English descriptors
- KwdEn :
- MESH :
- chemical , adverse effects : Antiviral Agents.
- chemical , classification : Antiviral Agents.
- diagnosis : Drug Hypersensitivity.
- etiology : Drug Hypersensitivity.
- therapy : Drug Hypersensitivity.
- Disease Management, Humans.
Abstract
Antiviral drugs used to treat HIV and hepatitis C are common causes of delayed drug hypersensitivities for which many of the more severe reactions have been recently shown to be immunogenetically mediated such as abacavir hypersensitivity where HLA-B(∗)57:01 is now used routinely as a screening test to exclude patients carrying this allele from abacavir prescription. Most antiviral drug allergies consist of mild to moderate delayed rash without other serious features (eg, fever, mucosal involvement, blistering rash, organ impairment. In these cases treatment can be continued with careful observation and symptomatic management and the discontinuation rate is low.
DOI: 10.1016/j.iac.2014.04.011
PubMed: 25017682
Links to Exploration step
pubmed:25017682Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Antiviral drug allergy.</title><author><name sortKey="Milpied Homsi, Brigitte" sort="Milpied Homsi, Brigitte" uniqKey="Milpied Homsi B" first="Brigitte" last="Milpied-Homsi">Brigitte Milpied-Homsi</name><affiliation><nlm:affiliation>Department of Dermatology, Saint-André Hospital, Bordeaux, WA 6150, France.</nlm:affiliation></affiliation></author><author><name sortKey="Moran, Ellen M" sort="Moran, Ellen M" uniqKey="Moran E" first="Ellen M" last="Moran">Ellen M. Moran</name><affiliation><nlm:affiliation>Division of infectious diseases, Institute of Immunology and Infectious Disease, Murdoch University, Murdoch, Western Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Phillips, Elizabeth J" sort="Phillips, Elizabeth J" uniqKey="Phillips E" first="Elizabeth J" last="Phillips">Elizabeth J. Phillips</name><affiliation><nlm:affiliation>Division of infectious diseases, Institute of Immunology and Infectious Disease, Murdoch University, Murdoch, Western Australia; Division of Infectious Diseases, Vanderbilt University Medical Center, 1161 21st Avenue South, A-2200, Medical Center North, Nashville, TN 37232-2582, USA. Electronic address: elizabeth.j.phillips@vanderbilt.edu.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:25017682</idno><idno type="pmid">25017682</idno><idno type="doi">10.1016/j.iac.2014.04.011</idno><idno type="wicri:Area/PubMed/Corpus">003575</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003575</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Antiviral drug allergy.</title><author><name sortKey="Milpied Homsi, Brigitte" sort="Milpied Homsi, Brigitte" uniqKey="Milpied Homsi B" first="Brigitte" last="Milpied-Homsi">Brigitte Milpied-Homsi</name><affiliation><nlm:affiliation>Department of Dermatology, Saint-André Hospital, Bordeaux, WA 6150, France.</nlm:affiliation></affiliation></author><author><name sortKey="Moran, Ellen M" sort="Moran, Ellen M" uniqKey="Moran E" first="Ellen M" last="Moran">Ellen M. Moran</name><affiliation><nlm:affiliation>Division of infectious diseases, Institute of Immunology and Infectious Disease, Murdoch University, Murdoch, Western Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Phillips, Elizabeth J" sort="Phillips, Elizabeth J" uniqKey="Phillips E" first="Elizabeth J" last="Phillips">Elizabeth J. Phillips</name><affiliation><nlm:affiliation>Division of infectious diseases, Institute of Immunology and Infectious Disease, Murdoch University, Murdoch, Western Australia; Division of Infectious Diseases, Vanderbilt University Medical Center, 1161 21st Avenue South, A-2200, Medical Center North, Nashville, TN 37232-2582, USA. Electronic address: elizabeth.j.phillips@vanderbilt.edu.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Immunology and allergy clinics of North America</title><idno type="eISSN">1557-8607</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (adverse effects)</term><term>Antiviral Agents (classification)</term><term>Disease Management</term><term>Drug Hypersensitivity (diagnosis)</term><term>Drug Hypersensitivity (etiology)</term><term>Drug Hypersensitivity (therapy)</term><term>Humans</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiviral Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="classification" xml:lang="en"><term>Antiviral Agents</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Drug Hypersensitivity</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Drug Hypersensitivity</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Drug Hypersensitivity</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Disease Management</term><term>Humans</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Antiviral drugs used to treat HIV and hepatitis C are common causes of delayed drug hypersensitivities for which many of the more severe reactions have been recently shown to be immunogenetically mediated such as abacavir hypersensitivity where HLA-B(∗)57:01 is now used routinely as a screening test to exclude patients carrying this allele from abacavir prescription. Most antiviral drug allergies consist of mild to moderate delayed rash without other serious features (eg, fever, mucosal involvement, blistering rash, organ impairment. In these cases treatment can be continued with careful observation and symptomatic management and the discontinuation rate is low.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25017682</PMID><DateCreated><Year>2014</Year><Month>07</Month><Day>14</Day></DateCreated><DateCompleted><Year>2015</Year><Month>03</Month><Day>30</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1557-8607</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>3</Issue><PubDate><Year>2014</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Immunology and allergy clinics of North America</Title><ISOAbbreviation>Immunol Allergy Clin North Am</ISOAbbreviation></Journal><ArticleTitle>Antiviral drug allergy.</ArticleTitle><Pagination><MedlinePgn>645-62, ix</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.iac.2014.04.011</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0889-8561(14)00059-9</ELocationID><Abstract><AbstractText>Antiviral drugs used to treat HIV and hepatitis C are common causes of delayed drug hypersensitivities for which many of the more severe reactions have been recently shown to be immunogenetically mediated such as abacavir hypersensitivity where HLA-B(∗)57:01 is now used routinely as a screening test to exclude patients carrying this allele from abacavir prescription. Most antiviral drug allergies consist of mild to moderate delayed rash without other serious features (eg, fever, mucosal involvement, blistering rash, organ impairment. In these cases treatment can be continued with careful observation and symptomatic management and the discontinuation rate is low.</AbstractText><CopyrightInformation>Copyright © 2014 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Milpied-Homsi</LastName><ForeName>Brigitte</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Saint-André Hospital, Bordeaux, WA 6150, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moran</LastName><ForeName>Ellen M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Division of infectious diseases, Institute of Immunology and Infectious Disease, Murdoch University, Murdoch, Western Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Phillips</LastName><ForeName>Elizabeth J</ForeName><Initials>EJ</Initials><AffiliationInfo><Affiliation>Division of infectious diseases, Institute of Immunology and Infectious Disease, Murdoch University, Murdoch, Western Australia; Division of Infectious Diseases, Vanderbilt University Medical Center, 1161 21st Avenue South, A-2200, Medical Center North, Nashville, TN 37232-2582, USA. Electronic address: elizabeth.j.phillips@vanderbilt.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AI103348</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Immunol Allergy Clin North Am</MedlineTA><NlmUniqueID>8805635</NlmUniqueID><ISSNLinking>0889-8561</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Clin Infect Dis. 2013 May;56(9):1330-9</RefSource><PMID Version="1">23362284</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2001 Sep 28;15(14):1843-8</RefSource><PMID Version="1">11579247</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Scand J Infect Dis. 2012 Oct;44(10):802-3</RefSource><PMID Version="1">22803794</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Immunity. 2008 Jun;28(6):822-32</RefSource><PMID Version="1">18549801</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Allergy Clin Immunol Pract. 2014 Jan-Feb;2(1):21-33</RefSource><PMID Version="1">24565765</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2002 Mar 30;359(9312):1121-2</RefSource><PMID Version="1">11943262</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pharmacogenomics J. 2012 Dec;12(6):499-506</RefSource><PMID Version="1">21862974</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Intern Med. 2004 Jul;43(7):630-1</RefSource><PMID Version="1">15335197</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Dermatol. 2013 Aug;40(8):587-95</RefSource><PMID Version="1">23734933</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Hepatol. 2014 Apr;60(4):891-3</RefSource><PMID Version="1">24333861</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Hepatol. 2012 Feb;56(2):455-63</RefSource><PMID Version="1">21884670</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2014 Aug 24;28(13):1891-901</RefSource><PMID Version="1">24911354</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2013 Mar 27;27(6):889-97</RefSource><PMID Version="1">23276806</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pharmacogenetics. 2004 Jun;14(6):335-42</RefSource><PMID Version="1">15247625</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Infect Dis. 2008 Apr 1;46(7):1111-8</RefSource><PMID Version="1">18444831</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Dermatol Online J. 2011;17(8):14</RefSource><PMID Version="1">21906494</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Clin Pharmacol. 2013 Nov;69(11):1909-16</RefSource><PMID Version="1">23774940</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Clin Pharmacol. 2003 Sep;59(5-6):457-62</RefSource><PMID Version="1">12920493</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pharmacogenomics. 2012 Aug;13(11):1285-306</RefSource><PMID Version="1">22920398</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pharmacogenet Genomics. 2009 Feb;19(2):139-46</RefSource><PMID Version="1">19104471</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2005 Jan 3;19(1):97-9</RefSource><PMID Version="1">15627041</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2008 Feb 19;22(4):540-1</RefSource><PMID Version="1">18301070</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Hepatology. 2012 Jun;55(6):2042-3</RefSource><PMID Version="1">22234749</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Dermatol. 2007 Nov;157(5):934-40</RefSource><PMID Version="1">17854362</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 2012 Jun 28;486(7404):554-8</RefSource><PMID Version="1">22722860</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Braz J Infect Dis. 2013 Mar-Apr;17(2):194-204</RefSource><PMID Version="1">23490868</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Ther. 1998 Nov-Dec;20(6):1071-92</RefSource><PMID Version="1">9916603</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2001 Jul 5;345(1):41-52</RefSource><PMID Version="1">11439948</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2001 Dec 7;15(18):2423-9</RefSource><PMID Version="1">11740193</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Postgrad Med. 2005 May;117(5):32-6, 39</RefSource><PMID Version="1">15948366</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2012 Jul 17;26(11):F21-9</RefSource><PMID Version="1">22617051</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2009 Apr 30;360(18):1839-50</RefSource><PMID Version="1">19403903</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Biochem Rev. 2013 Feb;34(1):15-38</RefSource><PMID Version="1">23592889</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Dermatol. 1993 Jan;129(1):92-6</RefSource><PMID Version="1">8420497</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pharmacogenomics. 2010 Jul;11(7):973-87</RefSource><PMID Version="1">20602616</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Curr Opin Allergy Clin Immunol. 2007 Aug;7(4):324-30</RefSource><PMID Version="1">17620824</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J STD AIDS. 2009 Apr;20(4):288-9</RefSource><PMID Version="1">19304981</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Infect Dis. 2011 Aug;53(4):341-8</RefSource><PMID Version="1">21810746</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Ther. 2002 Oct;24(10):1502-14</RefSource><PMID Version="1">12462283</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS Res Ther. 2009 Oct 21;6:22</RefSource><PMID Version="1">19845952</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Infection. 2004 Oct;32(5):306-7</RefSource><PMID Version="1">15624898</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Immunol Rev. 2012 Nov;250(1):158-66</RefSource><PMID Version="1">23046128</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Intern Med. 2004 Jul;43(7):533</RefSource><PMID Version="1">15335175</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 2012 Jun 19;109(25):9959-64</RefSource><PMID Version="1">22645359</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Allergol Int. 2006 Mar;55(1):1-8</RefSource><PMID Version="1">17075280</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Top Antivir Med. 2012 Oct-Nov;20(4):125-8</RefSource><PMID Version="1">23154251</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2008 Feb 7;358(6):568-79</RefSource><PMID Version="1">18256392</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>JAMA Dermatol. 2013 Feb;149(2):152-8</RefSource><PMID Version="1">23560295</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Pharmacother. 2002 Mar;36(3):430-2</RefSource><PMID Version="1">11895054</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2008 May 31;22(9):999-1007</RefSource><PMID Version="1">18520343</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Immunol Allergy Clin North Am. 2009 Aug;29(3):481-501</RefSource><PMID Version="1">19563993</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Invest Dermatol. 2000 Aug;115(2):149-53</RefSource><PMID Version="1">10951229</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2011 Jun 19;25(10):1271-80</RefSource><PMID Version="1">21505298</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2002 Nov 8;16(16):2223-5</RefSource><PMID Version="1">12409746</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2002 Mar 2;359(9308):727-32</RefSource><PMID Version="1">11888582</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 2012 Aug 15;206(4):469-77</RefSource><PMID Version="1">22811301</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Drugs. 2012 Apr 16;72(6):847-69</RefSource><PMID Version="1">22512366</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2005 Jun 10;19(9):979-81</RefSource><PMID Version="1">15905681</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Hepatol. 2012 Aug;57(2):470-2</RefSource><PMID Version="1">22387663</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Allergy. 2002 Oct;57(10):884-93</RefSource><PMID Version="1">12269933</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Int Assoc Provid AIDS Care. 2013 Jan-Feb;12(1):12-4</RefSource><PMID Version="1">23076664</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2006 Dec 7;355(23):2444-51</RefSource><PMID Version="1">17151366</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J STD AIDS. 2013 Aug;24(8):639-42</RefSource><PMID Version="1">23970584</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Clin Pharmacol. 2011 May;71(5):701-7</RefSource><PMID Version="1">21480949</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Invest Dermatol. 2008 Jan;128(1):35-44</RefSource><PMID Version="1">17805350</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2008 Oct 1;22(15):2025-33</RefSource><PMID Version="1">18784465</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Allergol Int. 2006 Mar;55(1):17-25</RefSource><PMID Version="1">17075282</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2001 May 25;15(8):1085-6</RefSource><PMID Version="1">11400003</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Antimicrob Chemother. 2008 Nov;62(5):879-88</RefSource><PMID Version="1">18653488</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Curr Allergy Asthma Rep. 2014 Mar;14(3):418</RefSource><PMID Version="1">24429903</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4180-5</RefSource><PMID Version="1">15024131</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J HIV Ther. 2003 May;8(2):42-7</RefSource><PMID Version="1">12838164</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2001 Sep 1;28(1):14-8</RefSource><PMID Version="1">11579272</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ther Adv Chronic Dis. 2012 May;3(3):113-21</RefSource><PMID Version="1">23251772</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 1994 Nov 10;331(19):1272-85</RefSource><PMID Version="1">7794310</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019468" MajorTopicYN="N">Disease Management</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004342" MajorTopicYN="N">Drug Hypersensitivity</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="NLM">NIHMS587641</OtherID><OtherID Source="NLM">PMC4140860</OtherID><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Abacavir</Keyword><Keyword MajorTopicYN="N">Altered peptide repertoire</Keyword><Keyword MajorTopicYN="N">Antiretroviral</Keyword><Keyword MajorTopicYN="N">Human leukocyte antigen</Keyword><Keyword MajorTopicYN="N">Major histocompatibility complex</Keyword><Keyword MajorTopicYN="N">Nevirapine</Keyword><Keyword MajorTopicYN="N">Telaprevir pharmacogenomics</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>7</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>7</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>3</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25017682</ArticleId><ArticleId IdType="pii">S0889-8561(14)00059-9</ArticleId><ArticleId IdType="doi">10.1016/j.iac.2014.04.011</ArticleId><ArticleId IdType="pmc">PMC4140860</ArticleId><ArticleId IdType="mid">NIHMS587641</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003575 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 003575 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:25017682
|texte= Antiviral drug allergy.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:25017682" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |